(Q61641053)

English

Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 ΔV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin

article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Characterization of immune responses elicited in mice by intranasal co-immunization with HIV-1 Tat, gp140 DeltaV2Env and/or SIV Gag proteins and the nontoxicogenic heat-labile Escherichia coli enterotoxin (English)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

molecular medicine

0 references

Escherichia coli

1 reference

based on heuristic

inferred from title

Antonella Caputo

1

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Riccardo Gavioli

5

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

author name string

Egidio Brocca-Cofano

2

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Arianna Castaldello

3

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Rebecca Voltan

4

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Aurelio Cafaro

8

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Indresh K Srivastava

6

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Susan W Barnett

7

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

language of work or name

0 references

publication date

15 January 2008

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

number of pages

14

1 reference

based on heuristic

inferred from page(s)

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

26

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

9

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

1214-1227

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

HIV vaccine design and the neutralizing antibody problem

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Clinical research. A setback and an advance on the AIDS vaccine front

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Antibody vs. HIV in a clash of evolutionary titans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The HIV-1 Envelope Glycoproteins: Fusogens, Antigens, and Immunogens

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Development of V2-deleted trimeric envelope vaccine candidates from human immunodeficiency virus type 1 (HIV-1) subtypes B and C.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Progress and obstacles in the development of an AIDS vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Problems and emerging approaches in HIV/AIDS vaccine development

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Nonstructural HIV proteins as targets for prophylactic or therapeutic vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Recent advances in the development of HIV-1 Tat-based vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Rational vaccine strategies against AIDS: background and rationale

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Criteria for selection of HIV vaccine candidates—general principles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Introduction: rational vaccine strategies against AIDS

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Vaccines based on the native HIV Tat protein and on the combination of Tat and the structural HIV protein variant ΔV2 Env

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Efficient systemic and mucosal responses against the HIV-1 Tat protein by prime/boost vaccination using the lipopeptide MALP-2 as adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Vaccination with DNA containing tat coding sequences and unmethylated CpG motifs protects cynomolgus monkeys upon infection with simian/human immunodeficiency virus (SHIV89.6P).

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Long-term protection against SHIV89.6P replication in HIV-1 Tat vaccinated cynomolgus monkeys.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The presence of anti-Tat antibodies is predictive of long-term nonprogression to AIDS or severe immunodeficiency: findings in a cohort of HIV-1 seroconverters

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Human immunodeficiency virus type 1 Rev- and Tat-specific cytotoxic T lymphocyte frequencies inversely correlate with rapid progression to AIDS.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Sequence conservation and antibody cross-recognition of clade B human immunodeficiency virus (HIV) type 1 Tat protein in HIV-1-infected Italians, Ugandans, and South Africans

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Candidate HIV-1 Tat vaccine development: from basic science to clinical trials

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Native HIV-1 Tat protein targets monocyte-derived dendritic cells and enhances their maturation, function, and antigen-specific T cell responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

HIV-1 tat protein modulates the generation of cytotoxic T cell epitopes by modifying proteasome composition and enzymatic activity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

HIV-1 Tat raises an adjuvant-free humoral immune response controlled by its core region and its ability to form cysteine-mediated oligomers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The Tat protein broadens T cell responses directed to the HIV-1 antigens Gag and Env: Implications for the design of new vaccination strategies against AIDS

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Perils at mucosal front lines for HIV and SIV and their hosts

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Mucosal HIV vaccines: where are we now?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Progress towards an AIDS mucosal vaccine: an overview

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

HIV swiftly guts the immune system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Antitumor efficacy of Venezuelan equine encephalitis virus replicon particles encoding mutated HPV16 E6 and E7 genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Antibody responses in volunteers induced by nasal influenza vaccine combined with Escherichia coli heat-labile enterotoxin B subunit containing a trace amount of the holotoxin

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

New generation of mucosal adjuvants for the induction of protective immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Mutants of the Escherichia coli heat-labile enterotoxin as safe and strong adjuvants for intranasal delivery of vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Enhancement of vaccine potency by fusing modified LTK63 into human papillomavirus type 16 chimeric virus-like particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Caprine herpesvirus 1 vaccine with the LTK63 mutant as a mucosal adjuvant induces strong protection against genital infection in goats.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The acquired immune response to the mucosal adjuvant LTK63 imprints the mouse lung with a protective signature.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Recent advances in immunological adjuvants: the development of particulate antigen delivery systems

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Phase I evaluation of intranasal trivalent inactivated influenza vaccine with nontoxigenic Escherichia coli enterotoxin and novel biovector as mucosal adjuvants, using adult volunteers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Induction of Broad and Potent Anti-Human Immunodeficiency Virus Immune Responses in Rhesus Macaques by Priming with a DNA Vaccine and Boosting with Protein-Adsorbed Polylactide Coglycolide Microparticles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Structure and mucosal adjuvanticity of cholera and Escherichia coli heat-labile enterotoxins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Mucosal vaccines: non toxic derivatives of LT and CT as mucosal adjuvants.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

DNA prime and protein boost immunization with innovative polymeric cationic core-shell nanoparticles elicits broad immune responses and strongly enhance cellular responses of HIV-1 tat DNA vaccination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Codon optimization of the tat antigen of human immunodeficiency virus type 1 generates strong immune responses in mice following genetic immunization

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Candidate HIV-1 gp140ΔV2, Gag and Tat vaccines protect against experimental HIV-1/MuLV challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Preparation and Characterization of Innovative Protein-coated Poly(Methylmethacrylate) Core-shell Nanoparticles for Vaccine Purposes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Immunostimulatory DNA-based vaccines elicit multifaceted immune responses against HIV at systemic and mucosal sites

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Therapeutic vaccination reduces HIV sequence variability

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

The HIV-1 matrix protein p17 can be efficiently delivered by intranasal route in mice using the TLR 2/6 agonist MALP-2 as mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Intranasal immunization with tetanus toxoid and CNF1 as a new mucosal adjuvant protects BALB/c mice against lethal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Improved vaccine protection from simian AIDS by the addition of nonstructural simian immunodeficiency virus genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Qualitative T-helper responses to multiple viral antigens correlate with vaccine-induced immunity to simian/human immunodeficiency virus infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Enhanced cellular immunity to SIV Gag following co-administration of adenoviruses encoding wild-type or mutant HIV Tat and SIV Gag

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Efficient protein boosting after plasmid DNA or recombinant adenovirus immunization with HIV-1 vaccine constructs

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Neutralizing antibodies against HIV -- back in the major leagues?

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Transfer of neutralizing IgG to macaques 6 h but not 24 h after SHIV infection confers sterilizing protection: implications for HIV-1 vaccine development.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Nonneutralizing antibodies are able to inhibit human immunodeficiency virus type 1 replication in macrophages and immature dendritic cells

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Macrophages and HIV infection: therapeutical approaches toward this strategic virus reservoir

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

HIV-1 and the hijacking of dendritic cells: a tug of war.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Replicating rather than nonreplicating adenovirus-human immunodeficiency virus recombinant vaccines are better at eliciting potent cellular immunity and priming high-titer antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

An adenovirus-based HIV subtype B prime/boost vaccine regimen elicits antibodies mediating broad antibody-dependent cellular cytotoxicity against non-subtype B HIV strains.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Mucosal AIDS vaccine reduces disease and viral load in gut reservoir and blood after mucosal infection of macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

Induction of optimal immune responses against human immunodeficiency virus at mucosal portals of entry

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

based on heuristic

inferred from DOI database lookup

Induction of antigen-specific antibodies in vaginal secretions by using a nontoxic mutant of heat-labile enterotoxin as a mucosal adjuvant

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

based on heuristic

inferred from DOI database lookup

Characterization of molecularly cloned simian-human immunodeficiency viruses causing rapid CD4+ lymphocyte depletion in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VACCINE.2007.12.030

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/J.VACCINE.2007.12.030

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

PubMed publication ID

1 reference

Europe PubMed Central

PubMed publication ID

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:18243435%20AND%20SRC:MED&resulttype=core&format=json

2 January 2020

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q61641053&oldid=1953488934"